Dr. Black on Sequencing of Immunotherapy in Bladder Cancer

Peter Black, MD, senior research scientist, Vancouver Prostate Center, associate professor, Department of Urologic Sciences, University of British Columbia, discusses sequencing of immunotherapy for patients with bladder cancer.

Bladder cancer now has many different therapies which has made the sequencing of treatments a question that needs to be answered, explains Black.

Currently, patients with metastatic bladder cancer would receive chemotherapy and then a checkpoint inhibitor, such as durvalumab (Imfinzi). If patients are cisplatin ineligible, atezolizumab (Tecentriq) is approved in that setting, states Black.